Covid-19 roundup: French regulators not ready to give molnupiravir the OK; Brii claims China’s first antibody is effective against Omicron
Merck’s potential Covid-19 treatment molnupiravir will not be used in France, French regulators said Friday.
The French National Authority of Health cited the potential impact of the Omicron variant, the fact that Regeneron’s mAb cocktail is more effective, and the pill’s own lack of efficacy as reasons for denying early access of the drug to patients experiencing mild to moderate cases of Covid-19. France has already pre-ordered hundreds of thousands of the pills, with the goal of treating 50,000 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.